Addex Therapeutics Past Earnings Performance
Past criteria checks 0/6
Addex Therapeutics's earnings have been declining at an average annual rate of -10.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 19.2% per year.
Key information
-10.8%
Earnings growth rate
4.5%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | -19.2% |
| Return on equity | -921.6% |
| Net Margin | -640.9% |
| Next Earnings Update | 06 May 2024 |
Recent past performance updates
Recent updates
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
May 11Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)
Jun 10Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Mar 07What Type Of Returns Would Addex Therapeutics'(VTX:ADXN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 12Revenue & Expenses BreakdownBeta
How Addex Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -11 | 5 | 0 |
| 30 Sep 23 | 2 | -11 | 5 | 0 |
| 30 Jun 23 | 2 | -13 | 6 | 0 |
| 31 Mar 23 | 2 | -17 | 6 | 0 |
| 31 Dec 22 | 1 | -21 | 7 | 0 |
| 30 Sep 22 | 1 | -22 | 7 | -9 |
| 30 Jun 22 | 2 | -21 | 6 | 0 |
| 31 Mar 22 | 2 | -19 | 7 | 0 |
| 31 Dec 21 | 3 | -15 | 6 | 0 |
| 30 Sep 21 | 5 | -13 | 6 | 9 |
| 30 Jun 21 | 4 | -13 | 6 | 0 |
| 31 Mar 21 | 4 | -11 | 5 | 0 |
| 31 Dec 20 | 4 | -13 | 6 | 0 |
| 30 Sep 20 | 3 | -14 | 5 | 0 |
| 30 Jun 20 | 3 | -15 | 5 | 0 |
| 31 Mar 20 | 3 | -16 | 5 | 0 |
| 31 Dec 19 | 3 | -15 | 5 | 0 |
| 30 Sep 19 | 2 | -13 | 5 | 0 |
| 30 Jun 19 | 3 | -12 | 5 | 0 |
| 31 Mar 19 | 5 | -6 | 4 | 0 |
| 31 Dec 18 | 7 | -2 | 3 | 0 |
| 30 Sep 18 | 6 | 0 | 2 | 0 |
| 30 Jun 18 | 6 | 1 | 1 | 0 |
| 31 Mar 18 | 3 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | -3 | 1 | 0 |
| 30 Sep 17 | 0 | -3 | 1 | 0 |
| 30 Jun 17 | 0 | -3 | 1 | 0 |
| 31 Mar 17 | 0 | -3 | 1 | 0 |
| 31 Dec 16 | 0 | -3 | 1 | 0 |
| 30 Sep 16 | 1 | -3 | 1 | 0 |
| 30 Jun 16 | 1 | -3 | 2 | 0 |
| 31 Mar 16 | 1 | -4 | 2 | 0 |
| 31 Dec 15 | 1 | -4 | 2 | 0 |
| 30 Sep 15 | 1 | -4 | 2 | 0 |
| 30 Jun 15 | 0 | -4 | 2 | 0 |
| 31 Mar 15 | 0 | -3 | 2 | 0 |
| 31 Dec 14 | 0 | -2 | 2 | 0 |
| 30 Sep 14 | 0 | -2 | 2 | 0 |
| 30 Jun 14 | 0 | -1 | 3 | 0 |
| 31 Mar 14 | 0 | -8 | 5 | 0 |
| 31 Dec 13 | 0 | -14 | 7 | 0 |
| 30 Sep 13 | 0 | -20 | 8 | 0 |
| 30 Jun 13 | 0 | -26 | 10 | 0 |
Quality Earnings: ADXN is currently unprofitable.
Growing Profit Margin: ADXN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADXN is unprofitable, and losses have increased over the past 5 years at a rate of 10.8% per year.
Accelerating Growth: Unable to compare ADXN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: ADXN has a negative Return on Equity (-921.57%), as it is currently unprofitable.